The recent demonstration that the histone methyltransferase, D0T1L and the acetylysine binding protein BRD4 are required for continued proliferation and survival for subsets of acute myelogenous leukemia (AML) cells points to epigenetic mechanisms as potential therapeutic targets in this disease. Small molecule inhibitors of D0T1L and BRD4 have been developed and show remarkable antiproliferative activity against AML cells providing further rationale for deeper characterization of these processes. The central hypothesis for this project is that small molecule inhibitors of epigenetic mechanisms will effectively target AML cells. We will assess this hypothesis through the use novel small molecules, chemical biological approaches, epigenomic analyses genetically engineered mouse models and genetic screens.
In specific Aim 1 we will define the mechanisms by which bromodomains inhibitors suppress Myc and E2F driven gene expression programs.
In specific Aim 1 1 we will define mechanisms of acquired resistance to small molecule bromodomain inhibitors. These studies will inform as to possible mechanisms of clinical resistance to such therapies, and illuminate the cellular pathways through which these molecules suppress proliferation and induce apoptosis.
In specific aim 3 we will assess compelling combinations of small molecule inhibitors of epigenetic pathways including the combination of DOTI L inhibitors and BET inhibitors. Given our access to newly developed small molecule inhibitors, the proposed studies have the potential to bring new, more efficacious, less toxic therapies to children and adults diagnosed with AML.
Recent discoveries suggest that targeting epigeneitc mechansims will be a new approach to cancer therapy. We have recently discovered two proteins that influence gene expression via epigenetic mechasnisms which are required for survival of acute myelogenous leuekmia cells. In this proposal we will define the mechanism of action of these proteins, define mechansims of resitance to inhibtiors of these epigenetic mechanisms, and begin to translate these approaches to clinical assessment.
|Wan, Liling; Wen, Hong; Li, Yuanyuan et al. (2017) ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543:265-269|
|Weisberg, Ellen L; Puissant, Alexandre; Stone, Richard et al. (2017) Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 8:52026-52044|
|Pallis, Monica; Burrows, Francis; Ryan, Jeremy et al. (2017) Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget 8:16220-16232|
|Tamura, Akihiro; Hirai, Hideyo; Yokota, Asumi et al. (2017) C/EBP? is required for survival of Ly6C- monocytes. Blood 130:1809-1818|
|Toska, Eneda; Osmanbeyoglu, Hatice U; Castel, Pau et al. (2017) PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355:1324-1330|
|Shortt, Jake; Ott, Christopher J; Johnstone, Ricky W et al. (2017) A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer 17:160-183|
|Gonzalez, David; Luyten, Annouck; Bartholdy, Boris et al. (2017) ZNF143 is an important regulator of the myeloid transcription factor C/EBP?. J Biol Chem :|
|Tothova, Zuzana; Krill-Burger, John M; Popova, Katerina D et al. (2017) Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell 21:547-555.e8|
|Valerio, Daria G; Xu, Haiming; Chen, Chun-Wei et al. (2017) Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res 77:1753-1762|
|Li, Hubo; Mar, Brenton G; Zhang, Huadi et al. (2017) The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 129:497-508|
Showing the most recent 10 out of 303 publications